ArticleOncoimmunology2015
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 72 citations in OpenAlex.
- Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA oncology · 2017Trial
- PD-L1 restrains PD-1Cell reports · 2024Article
- Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.Genes & genomics · 2023Article
- Clinical features and treatment outcomes of progressive uveal melanoma.Archive of clinical cases · 2023Article
- Article
- Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.Journal of hematology & oncology · 2022Review
- CD8+ T cell-associated genes MS4A1 and TNFRSF17 are prognostic markers and inhibit the progression of colon cancer.Frontiers in oncology · 2022Article
- Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.Cell death & disease · 2021Article
- TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.Nature communications · 2021Article
- Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.Journal of translational medicine · 2021Article
- Molecular features and gene expression signature of metastatic colorectal cancer (Review).Oncology reports · 2021Review
- MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment.Cellular immunology · 2021Article
- Malignant Melanoma With Neuroendocrine Differentiation: A Case Report and Literature Review.Frontiers in oncology · 2021Article
- Bacteria-related changes in host DNA methylation and the risk for CRC.Gut microbes · 2020Review
- Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.BMC cancer · 2020Article
- Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.Frontiers in immunology · 2020Article
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.Frontiers in immunology · 2020Review
- Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells.Cancers · 2019Review
- Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase.Oncogene · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better prognosis than subjects with Stage I neoplasms exhibiting no or poor immune infiltration. Thus, immunological parameters have a superior prognostic value for CRC patients than TNM staging or the Dukes classification. In spite of the fact that CRC is the first neoplasia found to be under immunological control, most attempts made so far to cure this malignancy with immunotherapy have failed. With the exception of a minority of lesions characterized by microsatellite instability (MSI), CRC seems to be insensitive to the blockade of immunological checkpoints with monoclonal antibodies (mAbs) specific for cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) and the PD-1 ligand CD274 (best known as PD-L1). Thus, CRC stands in contrast with an increasing number of malignancies that respond to checkpoint blockers. Efforts should therefore be dedicated to the development of strategies to (re)instate immunosurveillance in patients with MSI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.